Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PoC-HCV Genedrive Viral Detection Assay Validation Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02992184
Recruitment Status : Completed
First Posted : December 14, 2016
Last Update Posted : December 14, 2016
Sponsor:
Collaborator:
EPISTEM
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

Brief Summary:
The principal objective is to assess the diagnostic accuracy of the PoC assay (Genedrive, Epistem) to detect HCV RNA against the reference standard of commercial real-time polymerase chain reaction (RT-PCR) assay (RealTime HCV, Abbott) using stored heparinized plasma from patients with chronic hepatitis C and non-infected controls.

Condition or disease Intervention/treatment
Hepatitis C Device: HCV RNA detection with Genedrive assay Device: HCV RNA detection with RealTime HCV

Layout table for study information
Study Type : Observational
Actual Enrollment : 417 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Study Start Date : September 2016
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
HCV patients
228 HCV patients
Device: HCV RNA detection with Genedrive assay
Other Name: HCV RNA detection with Point of Care assay

Device: HCV RNA detection with RealTime HCV
Other Name: HCV RNA detection with RT-PCR assay

control
189 controls
Device: HCV RNA detection with Genedrive assay
Other Name: HCV RNA detection with Point of Care assay

Device: HCV RNA detection with RealTime HCV
Other Name: HCV RNA detection with RT-PCR assay




Primary Outcome Measures :
  1. Accuracy of HCV RNA detection with PoC assay (Genedrive, Epistem) vs reference standard of commercial real-time polymerase chain reaction (RT-PCR) assay (RealTime HCV, Abbott). [ Time Frame: pre-treatment ]
    Assess the diagnostic accuracy of the PoC assay (Genedrive, Epistem) to detect HCV RNA against the reference standard of commercial real-time polymerase chain reaction (RT-PCR) assay (RealTime HCV, Abbott) using stored heparinized plasma from patients with chronic hepatitis C and non-infected controls (with Genedrive channel acceptance set at 2 out of 3).


Secondary Outcome Measures :
  1. Diagnostic algorithm optimization [ Time Frame: Pre-treatment ]
    To optimize the diagnostic algorithm (i.e., 1, 2, or 3 out of 3 channels; repeat testing or not) that gives the optimal balance between sensitivity and specificity for detection of HCV RNA.

  2. Factors associated with false-positive of false-negative results [ Time Frame: Pre-treatment ]
    To identify factors associated with false-positive or false-negative results of the PoC assay.

  3. Assess the inter-examiner reproducibility of the PoC assay. [ Time Frame: Pre-treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Pre-treatment cohort: 228 HCV patients samples

  • Age > 18 years old.
  • Patients with positive HCV RNA.
  • Heparinized plasma samples are available before the initiation of antiviral HCV therapy.
  • Patients have given a written consent that their blood samples will be further used for research.

Control samples : 189 controls

  • Age > 18 years old.
  • Participants were tested negative for anti-HCV antibody
  • Heparinized plasma samples are available
  • Participants have given a written consent that their blood samples will be further used for research
Criteria

Inclusion Criteria:

Criteria for case

  • Age > 18 years old.
  • Patients with positive HCV RNA.
  • Heparinized plasma samples are available before the initiation of antiviral HCV therapy.
  • Patients have given a written consent that their blood samples will be further used for research.

Criteria for control

  • Age > 18 years old.
  • Participants were tested negative for anti-HCV antibody
  • Heparinized plasma samples are available
  • Participants have given a written consent that their blood samples will be further used for research

Exclusion Criteria:

-

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier: NCT02992184    
Other Study ID Numbers: ANRS HC POC VIRAL DETECTION
First Posted: December 14, 2016    Key Record Dates
Last Update Posted: December 14, 2016
Last Verified: December 2016
Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
HCV
Genedrive
Point of Care
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis C
Hepatitis
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections